Direxion Daily CSI China Internet Bull 2X Shares vs Stryker Corporation — how do they compare? Direxion Daily CSI China Internet Bull 2X Shares trades at $18.62 (market cap $173.62M), while Stryker Corporation trades at $276.9 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 611.9× Direxion Daily CSI China Internet Bull 2X Shares's market cap, and Stryker Corporation pays a 1.27% dividend while Direxion Daily CSI China Internet Bull 2X Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily CSI China Internet Bull 2X Shares for 24 Days and Stryker Corporation for 20 Days on average.
| CWEB | SYK | |
|---|---|---|
Market Cap | $173.62M | $106.24B |
Volume | 551,726 | 2,982,001 |
Sector | Leveraged / Inverse | Health |
52-Week High | $55.62 | $388.35 |
52-Week Low | $17.39 | $269.75 |
Typical Hold Time | 24 Days | 20 Days |
Enterprise Value | — | $117.70B |
Dividend Yield | — | 1.27% |
Signals from Pluang's Aura AI — not financial advice
CWEB is trading at $18.02, down 1.85% on the day, with technical indicators showing a bearish trend across moving averages. The stock faces selling pressure with all 13 moving average signals bearish and key resistance levels clustered around $18. Recent news highlights China's AI ambitions and potential growth in China tech stocks as catalysts.
The outlook remains cautious due to technical weakness, though exposure to China's growing AI sector offers long-term potential. Key risks include China market volatility and competitive pressures. Investors should monitor earnings reports for fundamental validation of growth prospects.
Stryker Corporation (SYK) trades at $275.40, down 1.11% amid bearish technical signals and recent negative news regarding manufacturing issues. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $3.69 versus $3.49 expected, and profitability metrics remain robust with a 14.43% net income margin. Analyst consensus remains overwhelmingly bullish with a $368.11 price target representing 33% upside potential.
Despite near-term headwinds from manufacturing disclosures and legal investigations, Stryker's solid earnings track record, strong cash flow generation, and dominant medical technology position support long-term growth prospects. Key risks include ongoing legal scrutiny and competitive pressures in the medtech sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
CWEB is a leveraged ETF that seeks to provide two times (2x) the daily performance of the CSI China Internet Index. It offers magnified exposure to top Chinese internet companies listed on US and Hong Kong exchanges.
Read more on CWEB →Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →